A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-4-(methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients.
Our laboratory has described a drug-responsive NADH oxidase activity of the external surface of the plasma membrane of HeLa and other cancer cells, but not from normal cells, that was shed into media conditioned by the growth of cancer cells such as HeLa. The shed form of the activity exhibited the same drug responsiveness as the plasma membrane-associated form. In this study, sera from tumor-bearing and control rats, cancer patients, normal volunteers, and patients with diseases other than cancer were collected and assayed for a cancer-specific form of NADH oxidase responsive to the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984). With sera from tumor-bearing rats and cancer patients, LY181984 added at a final concentration of 1 microM either inhibited or stimulated the activity. With sera from control rats, normal volunteers, or patients with disorders other than cancer, the drug was without effect on the NADH oxidase activity of the sera. The activity altered by the antitumor sulfonylurea was present both in freshly collected sera and in sera stored frozen. Inhibition was half maximal at about 30 nM LY181984. The sulfonylurea-altered activity was found in sera of nearly 200 cancer patients including patients with solid cancers (e.g., breast, prostate, lung, ovarian) and with leukemias and lymphomas. We postulate that the serum presence of the antitumor sulfonylurea-responsive NADH oxidase represents an origin due to shedding from the patient's cancer. If so, the antitumor-responsive NADH oxidase would represent the first reported cell surface change universally associated with all forms of human cancer.